Heart failure & cardiomyopathiesMeta-analysis
Global prevalence of myocardial fibrosis among individuals with cardiometabolic conditions: a systematic review and meta-analysis
- Systematic review and meta-analysis
Authors' conclusion
This first global review estimates that one-third of individuals with cardiometabolic conditions develop MF, with the prevalence expected to rise.
Study context
- Population
- Individuals with cardiometabolic conditions (hypertension, T2DM, hyperlipidaemia, obesity), myocardial fibrosis (MF) assessed by biopsy or late gadolinium enhancement-cardiac magnetic resonance (LGE-CMR)52 articles
- Participants
- 5,921 individuals
- Outcome
- Global prevalence of myocardial fibrosis (MF)
Pooled result
As reported in the abstract
Prevalence of MF
Overall MF prevalence
32.7%
Hypertension (highest prevalence)
35.2% (95% CI: 25.5-45.0)
Further pooled results
MF prevalence by assessment method
- Biopsy-based studies
- 75.6% (95% CI: 53.6-97.6)
- LGE-CMR studies
- 26.8% (95% CI: 20.6-33.0)
Factors associated with MF (narrative synthesis)
- Increased LV mass/LV hypertrophy, reduced LV function and myocardial stiffness
Original publication
Global prevalence of myocardial fibrosis among individuals with cardiometabolic conditions: a systematic review and meta-analysis. Eur J Prev Cardiol. Published 19 February 2025. doi:10.1093/eurjpc/zwaf083
Summarised from the published abstract; every number is checked against it